DOCSLIB.ORG

Annual Scientific Report 2009

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Scientific Report 2009 European Bioinformatics Institute Annual Scientific Report 2009 Annual Scientific Report 2009 European Bioinformatics Institute EMBL-European Bioinformatics Institute Wellcome Trust Genome Campus, Hinxton Cambridge CB10 1SD United Kingdom Tel. +44 (0)1223 494444, Fax +44 (0)1223 494468 www.ebi.ac.uk EMBL Heidelberg Meyerhofstraße 1 69117 Heidelberg Germany Tel. +49 (0)6221 387 0, Fax +49 (0)6221 387 8306 www.embl.org [email protected] EMBL Grenoble 6, rue Jules Horowitz, BP181 38042 Grenoble, Cedex 9 France Tel. +33 (0)4 76 20 72 69, Fax +33 (0)4 76 20 71 99 EMBL Hamburg c/o DESY Notkestraße 85 22603 Hamburg Germany Tel. +49 (0)40 89 902 110, Fax +49 (0)40 89 902 149 EMBL Monterotondo Adriano Buzzati-Traverso Campus Via Ramarini, 32 00015 Monterotondo (Rome) Italy Tel. +39 06900 91402, Fax +39 0690091406 Texts: EMBL-EBI Group and Team Leaders Layout, editing and cover design: Vienna Leigh, EMBL Office of Information and Public Affairs Louisa Wright, EMBL-EBI Outreach Programme Project Leader 3 Contents SECTION 1: INTRODUCTION 5 Foreword 7 Highlights of 2009 9 SECTION 2: SERVICES IN 2009 15 The Activities of the PANDA Group 17 The European Nucleotide Archive Team 31 Vertebrate Genomics 37 The Ensembl Genomes Team 45 The Proteomics Services Team 51 The InterPro Team 57 Computational Chemical Biology: the ChEMBL Team 61 Chemoinformatics and Metabolism 65 Database Research and Development 71 The GO Editorial Office 75 The Microarray Informatics Team 79 The Microarray Software Development Team 85 The Protein Data Bank in Europe (PDBe) Team 89 Developing and Integrating Tools for Biologists 93 Literature Resource Development 97 SECTION 3: RESEARCH IN 2009 103 The Bertone Group: differentiation and development 105 The Enright Group: functional genomics and analysis of small RNA function 111 The Goldman Group: evolutionary tools for sequence analysis 117 The Le Novère Group: computational systems neurobiology 123 The Luscombe Group: genome-scale analysis of regulatory systems 129 The Rebholz-Schuhmann Group: semantic standardisation of the scientific literature 135 The Thornton Group: computational biology of proteins 141 SECTION 4: SUPPORT IN 2009 147 Outreach and Training 149 Industry Support 159 Systems and Networking 163 External Services Team 165 4 SECTION 5: FACTS AND FIGURES 169 Services and Research 171 Publications 177 Major Database Collaborations 185 Scientific Advisory Boards 187 External Seminar Speakers 189 INDEX 191 Section 1 Introduction 5 Foreword 7 Highlights of 2009 9 6 Janet Thornton Graham Cameron Director Associate Director Foreword 7 Introduction Welcome to EMBL-EBI’s 2009 Annual Scientific Report. With the emergence of ever-more powerful sequencing and the need for improved translation of biological discover- ies into applications, EMBL-EBI’s mission, to provide bioinformatics services for biomolecular data, to perform basic bioinformatics research, to provide user training and to support industry, has never been more important. – Foreword This year has seen major developments in capturing and storing data from next-generation sequencing machines. These are powering many international projects, including the 1000 Genomes Project to reveal the molecular basis of human variation. With our international colleagues, the EBI is providing the public archive for the data generated. The computational and storage needs of all these projects are tremendous, and require an enormous growth in both the computer power and the storage needed to fulfil these commitments. This year has also seen ChEMBLdb go live. This is a freely available web resource for chemical biology and drug dis- covery research. ChEMBLdb provides worldwide access to a large number of medicinal chemistry lead optimisation experiments (usually known as Structure Activity Relationship, or SAR data) reported in the primary literature. The ChEMBLdb resource is highly complementary to existing resources such as UniProt, PDBe and ChEBI, but adds an important new capability to address the needs of the pharmaceutical and biotechnology industries, and the academic chemical biology communities with chemical data. The EBI’s research is diverse and flourishing, producing both exciting discoveries and the development of powerful new tools to handle the flood of data. We have contributed to understanding how genome structure affects its func- tion; to defining the repertoire of transcription factors, which provide regulatory mechanisms underlying biological processes in humans; and to elucidating the effect of deleting a component of the nutrient-responsive mTOR (mam- malian target of rapamycin) signalling pathway, which led to increased life span and resistance to age-related patholo- gies in mice. In parallel we have developed new resources, including leading the worldwide effort to develop a Systems Biology Graphical Notation, which is a new ‘language’ to describe and visualise all kinds of biological knowledge, from gene regulation to metabolism and cellular signalling. Our services are being used ever-more frequently by scientists in Europe and worldwide, with around 3 million web hits per day on the EBI website and over one million compute jobs per month run at the EBI. As the data resources develop, our commitment to providing training for users increases. This year we have run many new workshops and courses, both at Hinxton and throughout Europe, and participated in many conferences, in total reaching an estimated 24,000 researchers. Our Industry Programme has also grown, invigorated by the new computational chemistry devel- opments at the EBI and bringing new ideas both for services and for workshops. The Innovative Medicines Initiative (IMI), run by the European pharmaceutical industry and the European Commission, offers a welcome opportunity to address the needs of this sector more directly with explicit grant funding, involving the EBI in several new projects. The additional funding made available by EMBL Council in this indicative scheme is being used to consolidate the core set of data resources provided by EMBL-EBI, but longer-term funding is still precarious. The ELIXIR preparatory phase, which aims to develop a plan to construct and operate a sustainable infrastructure for biological information in Europe, is beginning to bear fruit. However, although two countries have already committed to this project, there is still much work to be done to define the scope and secure stable funding for this infrastructure for the future. All our efforts at the EBI rely on extensive interactions with colleagues in Europe and throughout the world. The deposition of new data, the daily exchange of information between data resources, the joint development of software tools, the sharing of curation tasks and the challenges of collaborative research have built an extensive community of collaborators. It remains our privilege and pleasure to work with them and together we will continue to aim for excel- lence in all that we do. Janet Thornton, Director Graham Cameron, Associate Director Janet Thornton, Director PhD 1973, King’s College & National Inst. For Medical Research, London. Postdoctoral research at the University of Oxford, NIMR & Birkbeck College, London. Lecturer, Birkbeck College 1983–1989. Professor of Biomolecular Structure, University College London since 1990. Bernal Professor at Birkbeck College, 1996–2002. Director of the Centre for Structural Biology at Birkbeck College and University College London, 1998–2001. Director of EMBL-EBI since 2001. 8 Graham Cameron, Associate Director Applications Programmer, EMBL Data Library, 1983–1983. Introduction Database Administrator, EMBL Data Library, 1983–1986. Manager, EMBL Data Library, 1986–1992. Project Leader overseeing the creation of EMBL-EBI Outstation, 1993–1994. Head of Services, EMBL-EBI, 1994–1998. Joint Head of EMBL-EBI, 1998–2001. – Foreword Associate Director of EMBL-EBI since 2001. Janet Thornton Graham Cameron Director Associate Director Highlights of 2009 9 SERVICES Introduction Enabling optimal exploitation of biomolecular information is at the heart of EMBL-EBI’s mission. The EBI services include the provision of biological databases and tools to explore them. Our constituency includes academic and com- mercial researchers throughout Europe and the world, and we form a European node in many global data-sharing – Highlights of 2009 collaborations (figure 1). These service activities are accompanied by extensive outreach and training (concentrated mostly in Europe) with a dedicated team (see page 149), and industry users receive targeted support through the EBI’s Industry Programme (page 159). 2009 has been an interesting year for these services. The familiar ever-increasing data flow rates perpetuate exponen- tial database growth curves, which are already etched on the retinas of service providers and funders. However, in 2009 striking qualitative changes have accompanied the familiar quantitative changes. This has resulted in new data resources, restructuring of existing resources and the demise of some obsolete resources. EMBL-Bank Ensembl Ensembl Genomes ArrayExpress UniProt InterPro IntAct PRIDE PDBe Reactome GO Figure 1. Map showing location of EMBL-EBI’s collaborations for the major databases. One of the most striking new resources is ChEMBLdb, a database of bioactive compounds (drugs and drug-like molecules) and their quantitative properties and bioactivities. Computer methods for the storage and exploitation of chemical information – now called cheminformatics – pre-date the existence
Load more

Recommended publications
  • Applied Category Theory for Genomics – an Initiative
    Applied Category Theory for Genomics { An Initiative Yanying Wu1,2 1Centre for Neural Circuits and Behaviour, University of Oxford, UK 2Department of Physiology, Anatomy and Genetics, University of Oxford, UK 06 Sept, 2020 Abstract The ultimate secret of all lives on earth is hidden in their genomes { a totality of DNA sequences. We currently know the whole genome sequence of many organisms, while our understanding of the genome architecture on a systematic level remains rudimentary. Applied category theory opens a promising way to integrate the humongous amount of heterogeneous informations in genomics, to advance our knowledge regarding genome organization, and to provide us with a deep and holistic view of our own genomes. In this work we explain why applied category theory carries such a hope, and we move on to show how it could actually do so, albeit in baby steps. The manuscript intends to be readable to both mathematicians and biologists, therefore no prior knowledge is required from either side. arXiv:2009.02822v1 [q-bio.GN] 6 Sep 2020 1 Introduction DNA, the genetic material of all living beings on this planet, holds the secret of life. The complete set of DNA sequences in an organism constitutes its genome { the blueprint and instruction manual of that organism, be it a human or fly [1]. Therefore, genomics, which studies the contents and meaning of genomes, has been standing in the central stage of scientific research since its birth. The twentieth century witnessed three milestones of genomics research [1]. It began with the discovery of Mendel's laws of inheritance [2], sparked a climax in the middle with the reveal of DNA double helix structure [3], and ended with the accomplishment of a first draft of complete human genome sequences [4].
    [Show full text]
  • Gene Prediction: the End of the Beginning Comment Colin Semple
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central http://genomebiology.com/2000/1/2/reports/4012.1 Meeting report Gene prediction: the end of the beginning comment Colin Semple Address: Department of Medical Sciences, Molecular Medicine Centre, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK. E-mail: [email protected] Published: 28 July 2000 reviews Genome Biology 2000, 1(2):reports4012.1–4012.3 The electronic version of this article is the complete one and can be found online at http://genomebiology.com/2000/1/2/reports/4012 © GenomeBiology.com (Print ISSN 1465-6906; Online ISSN 1465-6914) Reducing genomes to genes reports A report from the conference entitled Genome Based Gene All ab initio gene prediction programs have to balance sensi- Structure Determination, Hinxton, UK, 1-2 June, 2000, tivity against accuracy. It is often only possible to detect all organised by the European Bioinformatics Institute (EBI). the real exons present in a sequence at the expense of detect- ing many false ones. Alternatively, one may accept only pre- dictions scoring above a more stringent threshold but lose The draft sequence of the human genome will become avail- those real exons that have lower scores. The trick is to try and able later this year. For some time now it has been accepted increase accuracy without any large loss of sensitivity; this deposited research that this will mark a beginning rather than an end. A vast can be done by comparing the prediction with additional, amount of work will remain to be done, from detailing independent evidence.
    [Show full text]
  • SD Gross BFI0403
    Janet Thornton Bioinformatician avant la lettre Michael Gross B ioinformatics is very much a buzzword of our time, with new courses and institutes dedicated to it sprouting up almost everywhere. Most significantly, the flood of genome data has raised the gen- eral awareness of the need to deve-lop new computational approaches to make sense of all the raw information collected. Professor Janet Thornton, the current director of the European Bioinformatics Institute (EBI), an EMBL outpost based at the Hinxton campus near Cambridge, has been in the field even before there was a word for it. Coming to structural biology with a physics degree from the University of Nottingham, she was already involved with computer-generated structural im- ages in the 1970s, when personal comput- ers and user-friendly programs had yet to be invented. The Early Years larities. Within 15 minutes, the software From there to the EBI, her remarkable Janet Thornton can check all 2.4 billion possible re- career appears to be organised in lationships and pick the ones relevant decades. During the 1970s, she did doc- software to compare structures to each to the question at hand. In comparison toral and post-doctoral research at other, recognise known folds and spot to publicly available bioinformatics the Molecular Biophysics Laboratory in new ones. Such work provides both packages such as Blast or Psiblast, Oxford and at the National Institute for fundamental insights into the workings Biopendium can provide an additional Medical Research in Mill Hill, near Lon- of evolution on a molecular level, and 30 % of annotation, according to Inphar- don.
    [Show full text]
  • The EMBL-European Bioinformatics Institute the Hub for Bioinformatics in Europe
    The EMBL-European Bioinformatics Institute The hub for bioinformatics in Europe Blaise T.F. Alako, PhD [email protected] www.ebi.ac.uk What is EMBL-EBI? • Part of the European Molecular Biology Laboratory • International, non-profit research institute • Europe’s hub for biological data, services and research The European Molecular Biology Laboratory Heidelberg Hamburg Hinxton, Cambridge Basic research Structural biology Bioinformatics Administration Grenoble Monterotondo, Rome EMBO EMBL staff: 1500 people Structural biology Mouse biology >60 nationalities EMBL member states Austria, Belgium, Croatia, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the United Kingdom Associate member state: Australia Who we are ~500 members of staff ~400 work in services & support >53 nationalities ~120 focus on basic research EMBL-EBI’s mission • Provide freely available data and bioinformatics services to all facets of the scientific community in ways that promote scientific progress • Contribute to the advancement of biology through basic investigator-driven research in bioinformatics • Provide advanced bioinformatics training to scientists at all levels, from PhD students to independent investigators • Help disseminate cutting-edge technologies to industry • Coordinate biological data provision throughout Europe Services Data and tools for molecular life science www.ebi.ac.uk/services Browse our services 9 What services do we provide? Labs around the
    [Show full text]
  • Functional Effects Detailed Research Plan
    GeCIP Detailed Research Plan Form Background The Genomics England Clinical Interpretation Partnership (GeCIP) brings together researchers, clinicians and trainees from both academia and the NHS to analyse, refine and make new discoveries from the data from the 100,000 Genomes Project. The aims of the partnerships are: 1. To optimise: • clinical data and sample collection • clinical reporting • data validation and interpretation. 2. To improve understanding of the implications of genomic findings and improve the accuracy and reliability of information fed back to patients. To add to knowledge of the genetic basis of disease. 3. To provide a sustainable thriving training environment. The initial wave of GeCIP domains was announced in June 2015 following a first round of applications in January 2015. On the 18th June 2015 we invited the inaugurated GeCIP domains to develop more detailed research plans working closely with Genomics England. These will be used to ensure that the plans are complimentary and add real value across the GeCIP portfolio and address the aims and objectives of the 100,000 Genomes Project. They will be shared with the MRC, Wellcome Trust, NIHR and Cancer Research UK as existing members of the GeCIP Board to give advance warning and manage funding requests to maximise the funds available to each domain. However, formal applications will then be required to be submitted to individual funders. They will allow Genomics England to plan shared core analyses and the required research and computing infrastructure to support the proposed research. They will also form the basis of assessment by the Project’s Access Review Committee, to permit access to data.
    [Show full text]
  • Meeting Review: Bioinformatics and Medicine – from Molecules To
    Comparative and Functional Genomics Comp Funct Genom 2002; 3: 270–276. Published online 9 May 2002 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/cfg.178 Feature Meeting Review: Bioinformatics And Medicine – From molecules to humans, virtual and real Hinxton Hall Conference Centre, Genome Campus, Hinxton, Cambridge, UK – April 5th–7th Roslin Russell* MRC UK HGMP Resource Centre, Genome Campus, Hinxton, Cambridge CB10 1SB, UK *Correspondence to: Abstract MRC UK HGMP Resource Centre, Genome Campus, The Industrialization Workshop Series aims to promote and discuss integration, automa- Hinxton, Cambridge CB10 1SB, tion, simulation, quality, availability and standards in the high-throughput life sciences. UK. The main issues addressed being the transformation of bioinformatics and bioinformatics- based drug design into a robust discipline in industry, the government, research institutes and academia. The latest workshop emphasized the influence of the post-genomic era on medicine and healthcare with reference to advanced biological systems modeling and simulation, protein structure research, protein-protein interactions, metabolism and physiology. Speakers included Michael Ashburner, Kenneth Buetow, Francois Cambien, Cyrus Chothia, Jean Garnier, Francois Iris, Matthias Mann, Maya Natarajan, Peter Murray-Rust, Richard Mushlin, Barry Robson, David Rubin, Kosta Steliou, John Todd, Janet Thornton, Pim van der Eijk, Michael Vieth and Richard Ward. Copyright # 2002 John Wiley & Sons, Ltd. Received: 22 April 2002 Keywords: bioinformatics;
    [Show full text]
  • The ELIXIR Core Data Resources: ​Fundamental Infrastructure for The
    Supplementary Data: The ELIXIR Core Data Resources: fundamental infrastructure ​ for the life sciences The “Supporting Material” referred to within this Supplementary Data can be found in the Supporting.Material.CDR.infrastructure file, DOI: 10.5281/zenodo.2625247 (https://zenodo.org/record/2625247). ​ ​ Figure 1. Scale of the Core Data Resources Table S1. Data from which Figure 1 is derived: Year 2013 2014 2015 2016 2017 Data entries 765881651 997794559 1726529931 1853429002 2715599247 Monthly user/IP addresses 1700660 2109586 2413724 2502617 2867265 FTEs 270 292.65 295.65 289.7 311.2 Figure 1 includes data from the following Core Data Resources: ArrayExpress, BRENDA, CATH, ChEBI, ChEMBL, EGA, ENA, Ensembl, Ensembl Genomes, EuropePMC, HPA, IntAct /MINT , InterPro, PDBe, PRIDE, SILVA, STRING, UniProt ● Note that Ensembl’s compute infrastructure physically relocated in 2016, so “Users/IP address” data are not available for that year. In this case, the 2015 numbers were rolled forward to 2016. ● Note that STRING makes only minor releases in 2014 and 2016, in that the interactions are re-computed, but the number of “Data entries” remains unchanged. The major releases that change the number of “Data entries” happened in 2013 and 2015. So, for “Data entries” , the number for 2013 was rolled forward to 2014, and the number for 2015 was rolled forward to 2016. The ELIXIR Core Data Resources: fundamental infrastructure for the life sciences ​ 1 Figure 2: Usage of Core Data Resources in research The following steps were taken: 1. API calls were run on open access full text articles in Europe PMC to identify articles that ​ ​ mention Core Data Resource by name or include specific data record accession numbers.
    [Show full text]
  • C. Elegans Whole Genome Sequencing Reveals Mutational Signatures Related to Carcinogens and DNA Repair Deficiency
    Downloaded from genome.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press C. elegans whole genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency Authors: Bettina Meier * (1); Susanna L Cooke * (2); Joerg Weiss (1); Aymeric P Bailly (1,3); Ludmil B Alexandrov (2); John Marshall (2); Keiran Raine (2); Mark Maddison (2); Elizabeth Anderson (2); Michael R Stratton (2); Anton Gartner * (1); Peter J Campbell * (2,4,5). * These authors contributed equally to this project. Institutions: (1) Centre for Gene Regulation and Expression, University of Dundee, Dundee, UK. (2) Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK. (3) CRBM/CNRS UMR5237, University of Montpellier, Montpellier, France. (4) Department of Haematology, University of Cambridge, Cambridge, UK. (5) Department of Haematology, Addenbrooke’s Hospital, Cambridge, UK. Address for correspondence: Dr Peter J Campbell, Dr Anton Gartner, Cancer Genome Project, Centre for Gene Regulation and Expression, Wellcome Trust Sanger Institute, The University of Dundee, Hinxton CB10 1SA, Dow Street, Cambridgeshire, Dundee DD1 5EH UK. UK. Tel: +44 (0) 1223 494745 Phone: +44 (0) 1382 385809 Fax: +44 (0) 1223 494809 E-mail: [email protected] E-mail: [email protected] Running title: mutation profiling in C. elegans Keywords: mutation pattern, genetic and environmental factors, C. elegans, cisplatin, aflatoxin B1, whole-genome sequencing. Downloaded from genome.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press ABSTRACT Mutation is associated with developmental and hereditary disorders, ageing and cancer. While we understand some mutational processes operative in human disease, most remain mysterious.
    [Show full text]
  • Abstracts In
    ECCB 2014 Accepted Posters with Abstracts G: Bioinformatics of health and disease G01: Emile Rugamika Chimusa, Jacquiline Wangui Mugo and Nicola Mulder. Leveraging ancestry along the genome of admixed individuals to resolve missing heritability in disease scoring statistics Abstract: Human genetics has been haunted by the mystery of “missing heritability” of common traits. Although studies have discovered several variants associated with common diseases and traits, these variants typically appear to explain only a minority of the heritability. Resolving missing heritability, the difference between phenotypic variance explained by associated SNPs and estimates of narrow-sense heritability (h2), will inform strategies for disease mapping and prediction of complex traits. Among biased estimates of h2 due to epistatic interactions and rare variants not captured by genotyping arrays have been cited to be the most can be the most explanations for missing heritability. Here, we present an approach for estimating heritability of traits based on sharing local ancestry segments between pairs of unrelated individuals in an admixed population. From simulation data and real data, we demonstrated that our approach outperformed current approaches for estimating heritability of traits and holds values in admixture mapping for deconvoluting genes underlying ethnic differences in complex diseases risk. G02: Sylvain Mareschal, Pierre-Julien Viailly, Philippe Bertrand, Fabienne Desmots-Loyer, Elodie Bohers, Catherine Maingonnat, Karen Leroy, Thierry Fest and Fabrice Jardin. Next- Generation Sequencing applied to tailor targeted therapies in lymphoma: the RELYSE project Abstract: Non-Hodgkin Lymphomas (NHL) are lymphoid cell malignancies accounting for about 4% of all cancers, with an incidence rate of 12 cases per 100,000 and per year in Europe.
    [Show full text]
  • Deep Profiling of Protease Substrate Specificity Enabled by Dual Random and Scanned Human Proteome Substrate Phage Libraries
    Deep profiling of protease substrate specificity enabled by dual random and scanned human proteome substrate phage libraries Jie Zhoua, Shantao Lib, Kevin K. Leunga, Brian O’Donovanc, James Y. Zoub,d, Joseph L. DeRisic,d, and James A. Wellsa,d,e,1 aDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158; bDepartment of Biomedical Data Science, Stanford University, Stanford, CA 94305; cDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158; dChan Zuckerberg Biohub, San Francisco, CA 94158; and eDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158 Edited by Benjamin F. Cravatt, Scripps Research Institute, La Jolla, CA, and approved August 19, 2020 (received for review May 11, 2020) Proteolysis is a major posttranslational regulator of biology inside lysate and miss low abundance proteins and those simply not and outside of cells. Broad identification of optimal cleavage sites expressed in cell lines tested that typically express only half their and natural substrates of proteases is critical for drug discovery genomes (13). and to understand protease biology. Here, we present a method To potentially screen a larger and more diverse sequence that employs two genetically encoded substrate phage display space, investigators have developed genetically encoded substrate libraries coupled with next generation sequencing (SPD-NGS) that phage (14, 15) or yeast display libraries (16, 17). Degenerate DNA allows up to 10,000-fold deeper sequence coverage of the typical six- sequences (up to 107) encoding random peptides were fused to a to eight-residue protease cleavage sites compared to state-of-the-art phage or yeast coat protein gene for a catch-and-release strategy synthetic peptide libraries or proteomics.
    [Show full text]
  • Annual Scientific Report 2013 on the Cover Structure 3Fof in the Protein Data Bank, Determined by Laponogov, I
    EMBL-European Bioinformatics Institute Annual Scientific Report 2013 On the cover Structure 3fof in the Protein Data Bank, determined by Laponogov, I. et al. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nature Structural & Molecular Biology 16, 667-669. © 2014 European Molecular Biology Laboratory This publication was produced by the External Relations team at the European Bioinformatics Institute (EMBL-EBI) A digital version of the brochure can be found at www.ebi.ac.uk/about/brochures For more information about EMBL-EBI please contact: [email protected] Contents Introduction & overview 3 Services 8 Genes, genomes and variation 8 Molecular atlas 12 Proteins and protein families 14 Molecular and cellular structures 18 Chemical biology 20 Molecular systems 22 Cross-domain tools and resources 24 Research 26 Support 32 ELIXIR 36 Facts and figures 38 Funding & resource allocation 38 Growth of core resources 40 Collaborations 42 Our staff in 2013 44 Scientific advisory committees 46 Major database collaborations 50 Publications 52 Organisation of EMBL-EBI leadership 61 2013 EMBL-EBI Annual Scientific Report 1 Foreword Welcome to EMBL-EBI’s 2013 Annual Scientific Report. Here we look back on our major achievements during the year, reflecting on the delivery of our world-class services, research, training, industry collaboration and European coordination of life-science data. The past year has been one full of exciting changes, both scientifically and organisationally. We unveiled a new website that helps users explore our resources more seamlessly, saw the publication of ground-breaking work in data storage and synthetic biology, joined the global alliance for global health, built important new relationships with our partners in industry and celebrated the launch of ELIXIR.
    [Show full text]
  • Human Genetics: International Projects and Personalized Medicine
    Drug Metabol Pers Ther 2016; 31(1): 3–8 Mini Review Maria Apellaniz-Ruiza, Cristina Gallegoa, Sara Ruiz-Pintoa, Angel Carracedo and Cristina Rodríguez-Antona* Human genetics: international projects and personalized medicine DOI 10.1515/dmpt-2015-0032 Received August 31, 2015; accepted October 19, 2015; previously Introduction published online November 18, 2015 Genetic variation databases describe naturally occur- Abstract: In this article, we present the progress driven ring genetic differences among individuals of the same by the recent technological advances and new revolu- species. This variation, accounting for 0.1% of our DNA tionary massive sequencing technologies in the field of [1], permits the flexibility and survival of a population human genetics. We discuss this knowledge in relation in the face of changing environmental circumstances, with drug response prediction, from the germline genetic but it also influences how people differ in their risk of variation compiled in the 1000 Genomes Project or in the disease or their response to drugs. It is well known that Genotype-Tissue Expression project, to the phenome- variability in response to drug therapy is the rule rather genome archives, the international cancer projects, such than the exception for most drugs, and these differences as The Cancer Genome Atlas or the International Cancer are among the major challenges in current clinical prac- Genome Consortium, and the epigenetic variation and its tice, drug development, and drug regulation [2, 3]. Thus, influence in gene expression, including the regulation of rather than accepting the “one drug fits all” approach, drug metabolism. This review is based on the lectures pre- researchers envision that drugs need to be tailored to fit sented by the speakers of the Symposium “Human Genet- the profile of each individual patient.
    [Show full text]